摘要
目的研究依达拉奉治疗急性大面积脑梗死的临床疗效及安全性。方法采取随机对照试验,将我院73例急性大面积脑梗死患者随机分为对照组(34例)及依达拉奉治疗组(39例),2组均给予脱水降颅内压、控制脑水肿、脑细胞保护剂(自由基清除剂除外)、神经营养剂等常规治疗;治疗组在此基础上加用依达拉奉30mg静滴,2次/d。2组疗程均为14d,治疗前和治疗后第7、14、21、28天对患者进行神经功能缺损评定及肝、肾功能检测,神经功能缺损采用美国国立卫生研究院卒中量表(NIHSS)评定,以治疗第28天病死率和NIHSS评分的改变作为主要疗效判断标准。结果治疗后治疗组神经功能缺损评分及病死率明显低于对照组,治疗组临床疗效明显优于对照组,2组比较差异有统计学意义(P<0.05);治疗组与对照组的不良反应比较差异无统计学意义(P>0.05)。结论依达拉奉治疗急性大面积脑梗死疗效显著,安全性高。
Objective To observe the clinical effect and safety of a new type of oxygen free radical scavenger, Edaravone,in treating massive cerebral infarction （MCI）. Methods Seventy-three patients of MCI were divided into Edaravone group（n= 39） and control group （n=34）. Both groups were treated with reducing intracranial pressure, neural protection etc. Additionally the patients in Edaravone group were administrated with the Edaravone injection. Before and 7d, 14d, 21d, 28d after the therapy, neural function defect evaluation（NIHSS） and the mortality were assessed. Clinical efficiency was evaluated aecording to changes of NIHSS and mortality scores between two groups on the 28th day. Results Grades of NIHSS and the mortality in Edaravone group were lower than those in control group, there was a significant difference between Edaravone group and control group（P〈0. 05）. Conclusion The new type of oxygen free radical scavenger, Edaravone,is effieient and safe in treating massive cerebral infarction.
出处
《中国实用神经疾病杂志》
2009年第4期5-8,共4页
Chinese Journal of Practical Nervous Diseases
